MedTrace Logo

Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

NCT05380401 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2025-09-24

No results posted yet for this study

Summary

A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.

Conditions

  • Premature

Interventions

DIETARY_SUPPLEMENT

Enfamil® DHA & ARA Supplement for Special Dietary Use

Dosage: 60 mg/kg/day of DHA and 120 mg/kg/day of ARA. Route of administration: enteral tube or by oral syringe

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Cynthia Blanco, MD, MSCI-TS · University of Texas Health Science Center San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
36 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-09
Primary Completion
2027-04-30
Completion
2028-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05380401 on ClinicalTrials.gov